Fixed-dose aspirin monotherapy compared with thromboelastography directed antiplatelet therapy in long-term management of left ventricular assist devices.
Sophia J FanelliMohammed ElzeneiniLauren E MeeceAhmad MahmoudEric I JengNeil HarrisMustafa M AhmedPublished in: Journal of cardiac surgery (2022)
Our study suggests the use of TEG led to increased doses of aspirin as well as adding a second antiplatelet agent, without improving outcomes in LVAD recipients. Furthermore, the removal of TEG from an LVAD-specific APT protocol did not worsen thromboembolic outcomes.
Keyphrases
- antiplatelet therapy
- acute coronary syndrome
- percutaneous coronary intervention
- left ventricular
- low dose
- acute myocardial infarction
- cardiovascular events
- randomized controlled trial
- heart failure
- coronary artery disease
- mitral valve
- open label
- clinical trial
- type diabetes
- metabolic syndrome
- aortic valve
- aortic stenosis